207 results on '"Kumada, Hiromitsu"'
Search Results
2. Impact of genetic polymorphism to personalized diet and exercise program for steatotic liver disease
3. Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study
4. Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors
5. Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
6. Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
7. Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma
8. Renal safety and biochemical changes for two years of tenofovir alafenamide after switching from long‐term other nucleotide analogues treatment in patients with chronic hepatitis B
9. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
10. Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
11. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir
12. Cover Image, Volume 92, Number 12, December 2020
13. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
14. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C
15. Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma
16. Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy
17. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2
18. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV‐infected Japanese Subjects in Phase 3 CERTAIN‐1 and CERTAIN‐2 Trials
19. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy
20. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection
21. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus
22. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues
23. Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases
24. No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection
25. Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
26. Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens
27. Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug
28. Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study
29. Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance
30. Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial
31. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens
32. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2
33. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens
34. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b
35. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir
36. Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus
37. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression
38. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
39. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride
40. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings
41. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens
42. Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas
43. Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs
44. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial
45. Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies
46. Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma
47. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection
48. Hepatic fat quantification using the two‐point Dixon method and fat color maps based on non‐alcoholic fatty liver disease activity score
49. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules
50. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.